Tweenvest Stocks

Adynxx, Inc. (OTCPK: ADYX)

Health Care · Biotechnology · US

$0.00

today · -50.0% 1Y

Adynxx, Inc. (OTCPK: ADYX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $581.00 and employs 6 people.

Over the last twelve months the share price has lost 50.0%, trading between 0.00 and 0.00.

Tweenvest scores Adynxx, Inc. across four factors: quality 6/100. Its strongest factor is quality.

ADYX price history

Not enough price history to draw a chart yet.

Key figures

Market cap
$581.00
Revenue (TTM)
P/E
EPS
-1.82
Dividend yield
Beta (5Y)
-53.39
52-week high
$0.00
52-week low
$0.00
Avg volume (3M)
Shares outstanding
5.81M
Employees
6
Next earnings

About Adynxx, Inc.

Adynxx, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating and commercializing novel transcription factor decoy technologies to combat pain and inflammatory conditions. Central to its efforts is the AYX platform of transcription factor decoys, which includes brivoligide, currently progressing through Phase II clinical development for reducing post-surgical discomfort. Additionally, AYX2 is a pre-clinical candidate being explored for its potential in treating localized chronic pain. Established in 2007, the company's corporate headquarters are situated in San Francisco, California.

ISIN
US00784D1037
Founded
2007
Listed since
Dec 18, 1998
Exchange
Pink Sheets LLC
Currency
USD
CompanyMarket capPriceDay
AbbVie Inc.NYSE: ABBV$468.22B$264.96+1.20%
Amgen Inc.NasdaqGS: AMGN$237.52B$439.33+1.29%
Gilead Sciences, Inc.NasdaqGS: GILD$181.18B$146.12+1.86%
Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX$138.91B$548.05+1.44%
Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN$83.28B$834.04+0.90%
argenx SEENXTBR: ARGX$65.85B902.00+1.90%
Moderna, Inc.NasdaqGS: MRNA$57.92B$145.13+0.04%
CSL LimitedASX: CSL$57.77BAU$168.30-1.69%

Browse every Biotechnology company →

Figures last refreshed Aug 18, 2026.